Niels Frimodt-Møller, Jon U Hansen, Michel Plattner, Douglas L Huseby, Stine Radmer Almind, Klara Haldimann, Marina Gysin, Anna Petersson, Onur Ercan, Lea Ganz, Diarmaid Hughes, Carina Vingsbo Lundberg, Sven N Hobbie
BACKGROUND: The aminoglycoside apramycin has been proposed as a drug candidate for the treatment of critical Gram-negative systemic infections. However, its potential in the treatment of drug-resistant bloodstream infections (BSIs) has yet to be assessed. METHODS: The resistance gene annotations of 40 888 blood culture isolates were analyzed. In vitro profiling of apramycin comprised cell-free translation assays, broth microdilution, and frequency of resistance determination...
April 21, 2024: International Journal of Antimicrobial Agents